Bristol Myers Still Confident in Autoimmune Therapy After Patient Death

Dow Jones10-30

Bristol Myers Squibb Chief Executive Chris Boerner defended the drugmaker's pipeline Thursday, expressing confidence in a cell therapy that has been paused while reminding investors a closely watched blood-thinner is just one of many drugs it is developing.

Last week, Bristol Myers said a patient in its multiple sclerosis study died. The company had paused studies earlier this year because of side effects but aims to restart trials early next year after determining the effects weren't related to the drug itself.

"We are excited to see the potential of this product," Boerner said on the company's earnings call, adding that Bristol would "continue to be rigorous in how we conduct the study" and "be transparent with the broader community."

Boerner and other executives highlighted several new therapies such as a new class of cancer treatments and a potential Alzheimer's psychosis drug that they hope will plug the impending revenue cliff caused by multiple blockbuster drugs going off patent, like blood-thinner Eliquis and immunotherapy treatment Opdivo.

He was more muted when discussing a blood thinner the company is developing with Johnson & Johnson. "It's an important opportunity for us. There's obviously a lot of focus," he said. "Of course, I would be remiss not to remind everyone that we need to put this study in the context of a much broader and very rich pipeline that we've got."

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment